share_log

Schwazze's Q1 2024 Financial Results: Takes A Hit In Colorado, Overall Cannabis Sales Up By 9%

Schwazze's Q1 2024 Financial Results: Takes A Hit In Colorado, Overall Cannabis Sales Up By 9%

Schwazze的2024年第一季度财务业绩:在科罗拉多州受到打击,大麻总销量增长了9%
Benzinga ·  05/15 18:14

Medicine Man Technologies, Inc., operating as Schwazze (OTC:SHWZ), announced its financial results for the first quarter ended March 31, 2024.

以Schwazze(场外交易代码:SHWZ)运营的Medicine Man Technologies, Inc. 公布了截至2024年3月31日的第一季度财务业绩。

Schwazze's interim CEO, Forrest Hoffmaster, commented on the results. "We delivered another period of revenue growth in Q1 as we further refined our retail strategy while contending with the prolonged competitive challenges in Colorado and New Mexico."

施瓦兹的临时首席执行官福雷斯特·霍夫马斯特对业绩发表了评论。“我们在应对科罗拉多州和新墨西哥州长期竞争挑战的同时,进一步完善了零售战略,在第一季度实现了又一个收入增长期。”

Operational And Strategic Developments

运营和战略发展

Schwazze has focused on enhancing its retail and wholesale strategies, including pricing, promotions and improving the in-store experience. The company reported that its Colorado sales were down 10% year-over-year due to lower volumes, but overall sales were up 9%, outperforming the market.

Schwazze一直致力于加强其零售和批发策略,包括定价、促销和改善店内体验。该公司报告称,由于销量减少,其科罗拉多州的销售额同比下降了10%,但总销售额增长了9%,跑赢了市场。

In New Mexico, despite the rapid increase in store counts, the company concentrated on high-quality products and customer experience, leading to strong performance.

在新墨西哥州,尽管门店数量迅速增加,但该公司仍专注于高质量的产品和客户体验,从而实现了强劲的业绩。

"Over the past four years we have rapidly scaled our footprint through 13 acquisitions, building a leading retail presence in both Colorado and New Mexico. We believe these initiatives, coupled with our operating playbook and strict cost controls, will enable us to return to stronger levels of profitability moving forward," Hoffmaster noted.

“在过去的四年中,我们通过13次收购迅速扩大了业务范围,在科罗拉多州和新墨西哥州建立了领先的零售业务。我们相信,这些举措,加上我们的运营手册和严格的成本控制,将使我们能够在未来恢复更强的盈利水平,” 霍夫马斯特指出。

Key Financial Metrics

关键财务指标

  • Total Revenue: $41.6 million in Q1 2024, up 4% from $40.0 million in Q1 2023.
  • Gross Profit: $17.9 million (43.1% of total revenue) in Q1 2024, down from $21.8 million (54.6% of total revenue) in Q1 2023.
  • Income (loss) from Operations: Loss of $2.7 million in Q1 2024, compared to income of $5.6 million in Q1 2023.
  • Net Loss: $16.1 million in Q1 2024, compared to net income of $1.7 million in Q1 2023.
  • Adjusted EBITDA: $7.3 million in Q1 2024, down from $14.5 million in Q1 2023.
  • Operating Cash Flow: Negative $3.7 million in Q1 2024, compared to negative $0.88 million in Q1 2023.
  • Operating Expenses: $20.6 million in Q1 2024, up from $16.2 million in Q1 2023.
  • 总收入:2024年第一季度为4,160万美元,较2023年第一季度的4,000万美元增长4%。
  • 毛利:2024年第一季度为1,790万美元(占总收入的43.1%),低于2023年第一季度的2180万美元(占总收入的54.6%)。
  • 运营收入(亏损):2024年第一季度亏损270万美元,而2023年第一季度的收入为560万美元。
  • 净亏损:2024年第一季度的净亏损为1,610万美元,而2023年第一季度的净收入为170万美元。
  • 调整后的息税折旧摊销前利润:2024年第一季度为730万美元,低于2023年第一季度的1,450万美元。
  • 运营现金流:2024年第一季度为负370万美元,而2023年第一季度为负88万美元。
  • 运营费用:2024年第一季度的2,060万美元,高于2023年第一季度的1,620万美元。

Financial Position

财务状况

As of March 31, 2024, Schwazze reported cash and cash equivalents of $13.2 million, down from $19.2 million on December 31, 2023. Total debt increased to $159.7 million from $156.8 million during the same period.

截至2024年3月31日,施瓦兹公布的现金及现金等价物为1,320万美元,低于2023年12月31日的1,920万美元。债务总额从同期的1.568亿美元增加到1.597亿美元。

To learn more about the cannabis business and how to invest in the sector, don't miss the opportunity to join us at the 19th Benzinga Cannabis Capital Conference in Chicago this October 8-9. Engage with top executives, investors, policymakers, and advocates to explore the industry's future. Secure your tickets now before prices increase by following this link.

要了解有关大麻业务以及如何投资该行业的更多信息,请不要错过参加将于10月8日至9日在芝加哥举行的第19届Benzinga大麻资本会议的机会。与高层管理人员、投资者、政策制定者和倡导者互动,探索该行业的未来。在价格上涨之前,立即通过以下方式保护您的门票 这个链接

Recent Operational Highlights

近期运营亮点

  • Expansion: Opened a new dispensary under the Everest Apothecary banner in Las Cruces, New Mexico, increasing its retail footprint to 34 stores.
  • Wholesale Growth: Achieved over 30% door penetration in Colorado and New Mexico.
  • Product Performance: Lowell Herb Co. pre-roll sales increased more than threefold quarter-over-quarter in Colorado, and Wana gummy sales doubled in New Mexico.
  • 扩张:在新墨西哥州拉斯克鲁塞斯以珠穆朗玛峰药剂师的旗帜开设了一家新药房,将其零售足迹增加到34家门店。
  • 批发增长:在科罗拉多州和新墨西哥州实现了超过30%的门店渗透率。
  • 产品业绩:洛厄尔香草公司在科罗拉多州的售前销售额同比增长了三倍以上,新墨西哥州的Wana软糖销售额翻了一番。

Photo: AI-Generated Image.

照片:人工智能生成的图像。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发